171 related articles for article (PubMed ID: 8258189)
1. Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat.
Los G; Tuyt L; van Vugt M; Schornagel J; Pinedo HM
Cancer Chemother Pharmacol; 1993; 32(6):425-33. PubMed ID: 8258189
[TBL] [Abstract][Full Text] [Related]
2. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin.
Los G; van Vugt MJ; Pinedo HM
Br J Cancer; 1994 Feb; 69(2):235-41. PubMed ID: 8297720
[TBL] [Abstract][Full Text] [Related]
3. Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action.
Los G; Verdegaal E; Noteborn HP; Ruevekamp M; de Graeff A; Meesters EW; ten Bokkel Huinink D; McVie JG
Biochem Pharmacol; 1991 Jul; 42(2):357-63. PubMed ID: 1859450
[TBL] [Abstract][Full Text] [Related]
4. Experimental studies of cis-diamminedichloroplatinum (II) and cis-diammine-1, 1-cyclobutandicarboxylate platinum (II) combination therapy for malignant gynecologic tumors.
Kato N
Asia Oceania J Obstet Gynaecol; 1993 Dec; 19(4):467-76. PubMed ID: 8135680
[TBL] [Abstract][Full Text] [Related]
5. Effect of tumor presence on cisplatin and carboplatin: disposition in the isolated, perfused tumor and skin flap.
Vaden SL; Williams PL; Page RL; Riviere JE
Cancer Chemother Pharmacol; 1993; 32(1):31-8. PubMed ID: 8462121
[TBL] [Abstract][Full Text] [Related]
6. [Probability of the combination use of cisplatin and carboplatin].
Kobayashi K; Hino M; Hayashihara K; Niitani H
Nihon Gan Chiryo Gakkai Shi; 1990 Nov; 25(11):2684-92. PubMed ID: 2277219
[TBL] [Abstract][Full Text] [Related]
7. [Phase I clinical study of combined cisplatin and carboplatin therapy in lung cancer].
Hayasaka S; Yoshinaga T; Kinuwaki E; Kiyama T; Fujino N
Gan To Kagaku Ryoho; 1992 Oct; 19(12):2011-6. PubMed ID: 1417008
[TBL] [Abstract][Full Text] [Related]
8. Effect of hyperthermia on cisplatin and carboplatin disposition in the isolated, perfused tumour and skin flap.
Vaden SL; Page RL; Williams PL; Riviere JE
Int J Hyperthermia; 1994; 10(4):563-72. PubMed ID: 7963811
[TBL] [Abstract][Full Text] [Related]
9. Carboplatin and cisplatin pharmacokinetics after intrapleural combination treatment in patients with malignant pleural effusion.
Lerza R; Vannozzi MO; Tolino G; Viale M; Bottino GB; Bogliolo G; Cerruti A; Castello G; Mencoboni M; Reggiardo G; Pannacciulli I; Esposito M
Ann Oncol; 1997 Apr; 8(4):385-91. PubMed ID: 9209670
[TBL] [Abstract][Full Text] [Related]
10. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
Chang MJ; Yu WD; Reyno LM; Modzelewski RA; Egorin MJ; Erkmen K; Vlock DR; Furmanski P; Johnson CS
Cancer Res; 1994 Oct; 54(20):5380-6. PubMed ID: 7923169
[TBL] [Abstract][Full Text] [Related]
11. Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA.
Los G; van Vugt MJ; den Engelse L; Pinedo HM
Biochem Pharmacol; 1993 Oct; 46(7):1229-37. PubMed ID: 8216374
[TBL] [Abstract][Full Text] [Related]
12. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.
Los G; Smals OA; van Vugt MJ; van der Vlist M; den Engelse L; McVie JG; Pinedo HM
Cancer Res; 1992 Mar; 52(5):1252-8. PubMed ID: 1737387
[TBL] [Abstract][Full Text] [Related]
13. [Intraperitoneal and intrathoracic administration of hydroxyapatite-carboplatin (HAp-CBDCA)].
Mohri N; Mizuno I; Akamo Y; Takeyama H; Manabe T
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1791-3. PubMed ID: 10560396
[TBL] [Abstract][Full Text] [Related]
14. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy.
Los G; Verdegaal EM; Mutsaers PH; McVie JG
Cancer Chemother Pharmacol; 1991; 28(3):159-65. PubMed ID: 1855272
[TBL] [Abstract][Full Text] [Related]
15. Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice.
Boughattas NA; Lévi F; Fournier C; Hecquet B; Lemaigre G; Roulon A; Mathé G; Reinberg A
J Pharmacol Exp Ther; 1990 Nov; 255(2):672-9. PubMed ID: 2243347
[TBL] [Abstract][Full Text] [Related]
16. The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat.
Los G; Mutsaers PH; Ruevekamp M; McVie JG
Cancer Lett; 1990 May; 51(2):109-17. PubMed ID: 2344588
[TBL] [Abstract][Full Text] [Related]
17. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer.
Lorusso D; Petrelli F; Coinu A; Raspagliesi F; Barni S
Gynecol Oncol; 2014 Apr; 133(1):117-23. PubMed ID: 24486604
[TBL] [Abstract][Full Text] [Related]
18. [Effect of intraperitoneal chemotherapy on experimental peritoneal dissemination of gastric cancer].
Yonemura Y; Endou Y; Tochiori S; Bando E; Kawamura T; Shimada T; Miyamoto K; Tanaka M; Sasaki T
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1635-9. PubMed ID: 16315893
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetic analysis of platinum in the continuous CDDP-CBDCA treatment; its relation to the changes of blood biochemistry].
Chen JT; Hasumi K
Gan To Kagaku Ryoho; 1995 Apr; 22(5):653-7. PubMed ID: 7717717
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3- dioxolane]platinum(II), as determined by ex vivo pharmacodynamics.
Kim DK; Kim HT; Tai JH; Cho YB; Kim TS; Kim KH; Park JG; Hong WS
Cancer Chemother Pharmacol; 1995; 37(1-2):1-6. PubMed ID: 7497577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
